The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
EPIK-B6: A phase 2, open-label, 2-part, multicenter study of alpelisib in combination with fulvestrant for men and postmenopausal women with PIK3CA mutation HR–positive, HER2-negative, advanced breast cancer, which progressed on/after aromatase inhibitor treatment in Japan.
 
Hiroji Iwata
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Lilly Japan; MSD; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly Japan; MSD; Novartis; Pfizer; Sanofi
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst)
 
Naoki Niikura
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Kyowa Kirin; Lilly Japan; MSD; Novartis; Pfizer; Taiho Pharmaceutical
Research Funding - Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Kirin; Lilly Japan; Mochida Pharmaceutical Co. Ltd.; Nihon Medi-Physics; Nippon Kayaku; Pfizer; Puma Biotechnology; Taiho Pharmaceutical; Takeda
 
Hirohiko Sueki
Stock and Other Ownership Interests - Kaken Pharmaceutical
Honoraria - Janssen; Otsuka; Takeda
Consulting or Advisory Role - Janssen; Novartis
 
Tomoyuki Aruga
Speakers' Bureau - AstraZeneca/Hong Kong; Chugai Pharma; Lilly Japan; Pfizer
Research Funding - Pfizer
 
Toru Mukohara
Honoraria - AstraZeneca; Chugai Pharma; Eisai; Kyowa Kirin; Lilly Japan; Novartis; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Eisai; Micin
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Eisai (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Sysmex (Inst)
 
Kokoro Kobayashi
Honoraria - Pfizer
 
Hiroyuki Yasojima
No Relationships to Disclose
 
Takahiro Nakayama
Consulting or Advisory Role - Daiichi Sankyo Pharmaceutical; Lilly Japan
Speakers' Bureau - AstraZeneca/Hong Kong; Chugai Pharma; Daiichi Sankyo Pharmaceutical; Eisai; Lilly Japan; Novartis; Pfizer; Taiho Pharmaceutical
 
Tatsuya Toyama
Consulting or Advisory Role - Daiichi Sankyo/UCB Japan
Speakers' Bureau - AstraZeneca; Chugai Pharma; Eisai; Kyowa Hakko Kirin; Lilly; Nippon Kayaku; Novartis; Pfizer; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Nippon Kayaku (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Takanori Ishida
Speakers' Bureau - Lilly O.; Pfizer; Roche
 
Toshinari Yamashita
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Lilly; Nippon Kayaku; Novartis; Pfizer; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Kyowa Hakko Kirin (Inst); Nihonkayaku (Inst); Taiho Pharmaceutical (Inst)
 
Masato Takahashi
Honoraria - AstraZeneca; Daiichi Sankyo/UCB Japan; Eisai; Lilly; MSD; Pfizer
Research Funding - Eisai (Inst); Nippon Kayaku (Inst)
 
Takaaki Fujii
Speakers' Bureau - AstraZeneca; Chugai Pharma; Daiichi Sanky; Eisai; Lilly Japan
Research Funding - eisai
 
Mona El-Hashimy
No Relationships to Disclose
 
Michelle Kristine Miller
Employment - Novartis Pharmaceuticals UK Ltd.
Stock and Other Ownership Interests - Novartis Pharmaceuticals UK Ltd.
Travel, Accommodations, Expenses - Novartis Pharmaceuticals UK Ltd.
Other Relationship - Novartis Pharmaceuticals UK Ltd.
 
Ryohei Kurihara
Employment - Novartis